<DOC>
	<DOCNO>NCT01927757</DOCNO>
	<brief_summary>To evaluate efficacy etanercept adult moderate-to-severe rheumatoid arthritis ( RA ) respond lose satisfactory response adalimumab use first biologic agent .</brief_summary>
	<brief_title>Evaluating Etanercept Use Patients With Moderate Severe Rheumatoid Arthritis Who Have Lost Response Adalimumab</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Able provide inform consent Diagnosed moderate severe rheumatoid arthritis least 6 month Active RA least 3 swollen tender joint Failure respond combination treatment adalimumab methotrexate ( must take combination least 3 month ) loss satisfactory response combination adalimumab methotrexate , take least 6 month ( currently take adalimumab must complete 2 week without prior start study drug ) Negative hepatitis B C Negative serum urine pregnancy test start study currently take ( stable dose ) 15 mg methotrexate weekly least 8 weeks/has take methotrexate least 12 week total low dose 10 mg per week permit documented intolerability Normal chest Xray within 3 month Negative test tuberculosis ( TB ) Class IV RA ( wheelchair bedbound ) Significant concurrent medical condition , include : ( uncontrolled type 1 diabetes , poorly control type 2 diabetes , symptomatic heart failure , myocardial infarction past year , history unstable angina within past year , uncontrolled hypertension , severe chronic pulmonary disease , major chronic inflammatory connective tissue disease RA , Multiple sclerosis , active malignancy , history cancer , alcoholic hepatitis history alcoholic liver disease ) Other inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>etanercept</keyword>
	<keyword>arthritis</keyword>
	<keyword>adalimumab failure respond</keyword>
	<keyword>loss response adalimumab</keyword>
	<keyword>ACR20</keyword>
	<keyword>methotrexate</keyword>
	<keyword>Swollen joint</keyword>
	<keyword>tender joint</keyword>
</DOC>